Status: Not yet recruiting
ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after randomization in participants with advanced HF with reduced ejection fraction(HFrEF).
Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Biopeutics Co., LtdUpdated: Dec 15, 2025Locations: 1
Eligibility criteria
Patients older than 18 years of age, of any gender/sex and race/ethnicity [+10]